Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/560,932	
INFORMATION DISCLOSURE				Filing Date	2006-05-05	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Yechezkel BARENHOLTZ	
				Group Art Unit: 1632	Conf. No.: 4072	
((use as many sheets	as n	ecessary)	Examiner Name	Not Yet Known	
Sheet	1	of	2	Attorney Docket Number	BARENHOLTZ 14	

			U.S. PAT	ENT DOCUMENTS	
Examiner nitials*	Cite No.1	Patent Number Number-Kind Code ^{2 (17} known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4897355 A	1990-01-30	EPPSTEIN et al.	
	AB	US-5334761 A	1994-08-02	GEBEYEHU et al.	
	AC	US-5659011 A	1997-08-19	J. J. WALDMANN	
	AD	US-5674908 A	1997-10-07	HACES et al.	
	AE	US-5783565 A	1998-07-21	LEE et al.	
	AF	US-6075012 A	2000-06-13	GEBEYEHU et al.	
	AG	US-6281371 A	2001-08-28	KLOESEL et al.	
*	АН	US-5171678	1992-12-15	Centre National de la Recherche Scientifique (CNRS)	
		U	S. PATENT APP	PLICATION PUBLICATIONS	
Examiner Initials*	Cite No.1	Publication Number Number-Kind Code ^{2 (IT} known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Al	US-2001/048939 A1	2001-12-06	ERBACHER et al.	
		US-			
		US-	*		
		US-			

		FOREI	GN PATENT DO	DCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
*	AJ	EP 0 394 111 A1	1990-10-24	Centre National de la Recherche Scientifique (CNRS)		
	AK	WO 03/066068 A1	2003-08-14	INTRADIGM CORP.		
	AL	WO 99/02190 A	1999-01-21	GENZYME CORP.		
	AM	WO 98/05678 A2	1998-02-12	O. KEIL et al.		Abs

A STATE OF THE PARTY OF THE PAR	reservation were the constraint for the first	
Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			Complete if Known		
			Application Number	10/560,932	
INFORMAT	TION DISCL	OSURE	Filing Date	2006-05-05	
STATEMENT BY APPLICANT			First Named Inventor	Yechezkel BARENHOLTZ	
O I Z X I Mood I W I Made I			Group Art Unit: 1632	Conf. No.: 4072	
(use as many sheets as necessary)			Examiner Name	Not Yet Known	
Sheet 2	of	2	Attorney Docket Number	BARENHOLTZ 14	

NON PATENT LITERATURE DOCUMENTS /OTHER INFORMATION						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²			
	AN	International Search Report mailed October 22, 2004 (corresponding PCT Appln. No. PCT/IL2004/000533).				
	AO	International Search Report mailed November 16, 2004 (corresponding PCT Appln. No. PCT/IL2004/000534).				
	AP	International Search Report mailed October 22, 2004 (corresponding PCT Appln. No. PCT/IL2004/000536).				
	AQ	Australian Patent Office Examination Report mailed June 30, 2006 (corresponding Singapore Application No. SG200508078-3).				
	AR	F. BRUNEL et al., "Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine", <u>Vaccine</u> Vol. 17, pages 2192-2203, 1999.				
	AS	K. EWERT et al., "Efficient Synthesis and Cell-Transfection Properties of a New Multivalent Cationic Lipid for Nonviral Gene Delivery", <u>J. Med. Chem.</u> Vol. 45, pages 5023-5029, 2002.				
	AT	P. L. FELGNER et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <u>Proc. Natl.</u> <u>Acad. Sci. USA</u> ., Vol. 84, pages 7413-7417, November 1987.				
	AU	X. GAO et al., "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells", <u>Biochim.</u> <u>Biophys. Acta.</u> Vol. 179, pages 280-285, 1999.				
	AV	B. GUY et al., "Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine", <u>Vaccine</u> , Vol. 19, pages 1794-1805, 2001.				
	AW M. A. ILIES et al., "Recent developments in cationic lipid-mediated gene delivery and gene therapy", Exc. Ther. Patents., Vol. 11, No. 11, pages 1729-1752, 2001.					
	AX K. M. LIMA et al., "Comparison of different delivery systems of vaccination for the induction of protection tuberculosis in mice", <u>Vaccine</u> , Vol. 19, pages 3518-3525, 2001.					
	AY	A. D. MILLER, "Cationic Liposomes for Gene Therapy", Chem. Int. Ed. Eng., Vol. 37, pages 1768-1785, 1987.				
	AZ	T. NAKANISHI et al., "Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins", <u>J. Controlled Release</u> , Vol. 61, pages 233-240, 1999.				
	ВА	M. SAMINATHAN et al., "Ionic and Structural Specificity Effects of Natural and Synthetic Polyamines on the Aggregation and Resolubilization of Single-, Double-, and Triple-stranded DNA", <u>Biochemistry</u> , Vol. 38, pages 3821-3830, 1999.				

A STREET AND PROPERTY AND PROPERTY OF STREET		
Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.